
Qureight
Turns clinical CT scans into evidence for respiratory drug trials.
Key Takeaways
- What it is
- Turns clinical CT scans into evidence for respiratory drug trials.
- Best for
- AI-Powered Imaging Biomarkers
- Global Imaging CRO Services
- Qureight Platform
- Rating
- 4.3/5
What is Qureight?
Qureight helps biopharma teams turn clinical CT scans and related patient data into usable evidence for lung and heart disease trials. Its platform combines image management, data quality control, central reads, clinical trial reporting, and machine learning analysis. The service is built for studies involving conditions such as idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, pulmonary hypertension, and bronchiectasis.
Qureight connects quantitative imaging biomarkers directly to clinical trial operations, including patient selection, endpoint assessment, treatment-response tracking, and cohort reporting. Its proprietary biomarkers include Lung8, Air8, Fibr8, Glass8, and Vascul8, which measure different aspects of lung structure and blood vessels from standard-of-care inspiratory CT scans.
Qureight is best for biopharma sponsors and clinical research teams that need regulated imaging operations plus disease-specific AI analysis. It is not a self-serve AI workspace, and public information does not show standard subscription access or published per-user pricing. The strongest fit is a sponsor looking for a managed imaging partner rather than a standalone model.
Who is Using Qureight?
Clinical Operations Managers
Trial delivery stays organized through site qualification, image intake, central reads, quality controls, and study reporting.
Radiologists
Radiology key opinion leaders support eligibility reads and consistent assessment across participating trial sites.
Data Scientists
Curated imaging and real-world clinical data support biomarker development, cohort enrichment, and synthetic control arms.
Clinical Scientists
Clinical scientists can track disease severity, treatment response, and predicted progression using quantitative CT measures.
Regulatory and Quality Leads
The platform's GxP, 21 CFR Part 11, ISO 13485, and ISO 27001 positioning supports regulated study processes.
Uncommon Use Cases
Synthetic control arms when placebo groups are impractical; early drug development, trial design, and toxicity analysis
Key Features
Rating Breakdown
Pricing Plans
Custom Pricing
- Pricing depends on the selected imaging services, biomarkers, data products, and trial requirements.
- Public materials do not list a standard monthly or per-user price.
Which Qureight plan should you pick?
Start with Custom Pricing if you are planning a clinical trial that needs managed imaging operations, AI endpoints, or respiratory data science support.
Custom Pricing
Good for biopharma sponsors and clinical research teams that need a study-specific combination of imaging CRO services, biomarkers, central reads, or data science products.
Qureight Use Cases
Respiratory Trial Endpoint Analysis
Quantitative CT biomarkers provide objective measures for disease severity, treatment response, and disease progression.
Outcome: More detailed imaging evidence for clinical trial decisions.
Patient Selection and Cohort Enrichment
Imaging data helps sponsors identify suitable participants and describe the baseline disease profile of an enrolled cohort.
Outcome: Better-defined trial populations.
Central Eligibility Reads
Expert readers assess eligibility scans through a managed imaging workflow designed for consistent trial review.
Outcome: Eligibility read turnaround stated by Qureight as 72 hours.
Synthetic Control Arms
Real-world clinical data and imaging measures provide a comparison group when a conventional placebo arm is difficult, inefficient, or unethical.
Outcome: An alternative evidence source for efficacy assessment.
Imaging Data Quality Management
Automated intake, de-identification, validation, and quality checks prepare CT data for analysis across global trial sites.
Outcome: Cleaner, more consistent imaging data.
Workflow Ideas with Qureight
Prepare CT Data for a Trial
- 1Receive scans through site uploads or SFTP transfers
- 2Remove personally identifiable information and unnecessary DICOM tags
- 3Run validation and quality checks before analysis
Build an AI Imaging Endpoint
- 1Select a Qureight biomarker for the disease area
- 2Apply quantitative analysis to eligible inspiratory CT scans
- 3Include the results in endpoint or cohort reporting
Run a Managed Imaging Study
- 1Set the imaging charter and site requirements
- 2Qualify sites and coordinate central eligibility reads
- 3Monitor image quality and deliver trial read-outs
How Qureight fits into your stack
Clinical Trial Imaging
Qureight fits between trial sites and the sponsor's study team, handling image intake, qualification, review, quality control, and reporting.
Medical Data Management
The platform curates CT scans and related healthcare data, including de-identification and removal of unnecessary DICOM tags.
AI Biomarker Analysis
Its deep learning models turn standard-of-care inspiratory CT scans into quantitative measures for respiratory disease trials.
Regulated Study Operations
Qureight positions the platform for GxP and 21 CFR Part 11 environments, with ISO 13485 and ISO 27001 certifications.
Real-World Evidence
Data science products connect quantitative imaging with real-world clinical data for synthetic control arms and cohort analysis.
Pros
- +Disease-specific biomarkers: Lung8, Air8, Fibr8, Glass8, and Vascul8 target measurable features in respiratory disease.
- +Regulated trial fit: The platform supports GxP and 21 CFR Part 11 requirements.
- +Managed delivery: Qureight combines imaging CRO operations, radiology reads, data curation, and AI analysis.
- +Fast eligibility reads: Qureight states a 72-hour turnaround for eligibility assessments.
Cons
- −Enterprise sales process: Public information does not show self-serve plans or standard subscription pricing.
- −Narrow clinical focus: The main offering centers on lung and heart disease trials.
- −Managed-service model: It is less suitable for individuals seeking a general-purpose image analysis tool.
Limitations & when to consider alternatives
Known limitations
- Contract-Based Access. Platform use is governed by a principal contract or other written approval, rather than open public registration.
- No Guaranteed Availability. Qureight's platform terms state that access may be suspended, withdrawn, or restricted for business and operational reasons.
- UK-Oriented Platform. The platform terms say it is designed for users in the UK, although it is available to people worldwide.
- Study-Specific Upload Rules. Uploading materials depends on the principal contract and the processes or training provided by Qureight.
Look elsewhere when
- You need a self-serve AI image analysis app with public monthly pricing.
- You want a general-purpose image model for non-clinical images.
- Your team needs a public developer API or mobile application.
- You need broad therapeutic coverage outside the lung and heart disease focus.
How to Use Qureight
- 1
Define the Study Need
Start with the disease area, imaging endpoint, patient-selection question, or trial workflow that needs support.
- 2
Choose the Delivery Model
Qureight can provide global imaging CRO services, AI-powered endpoints and analytics, data science products, or a combination.
- 3
Set the Imaging Workflow
Agree on site onboarding, scan transfer, eligibility criteria, quality controls, central reads, and reporting requirements.
- 4
Transfer and Curate Imaging Data
Provide CT scans through supported intake routes so Qureight can de-identify, organize, and validate the data.
- 5
Run Biomarker Analysis
Apply the relevant Qureight imaging biomarkers to quantify disease features and monitor changes over time.
- 6
Review Trial Outputs
Use central reads, cohort reports, endpoint results, and clinical insights to support study decisions.
Who is Qureight For?
Biopharma Sponsors
Sponsors can add quantitative imaging endpoints, cohort analysis, and managed imaging operations to respiratory clinical trials.
Clinical Trial Teams
Trial teams gain workflows for site activation, image handling, eligibility reads, data quality, and endpoint reporting.
Respiratory Drug Developers
Developers working in interstitial lung disease, pulmonary hypertension, or bronchiectasis can use disease-focused imaging analysis.
Imaging and Biomarker Researchers
Researchers can work with curated imaging and clinical datasets to study disease severity, progression, and treatment response.
Clinical Research Organizations
CRO teams can add specialized imaging science and AI-derived endpoints to broader trial delivery programs.
Frequently Asked Questions
What does Qureight do?
Qureight provides imaging CRO services, AI-powered CT biomarkers, clinical trial imaging workflows, and data science products for biopharma studies.
Which diseases does Qureight focus on?
Its public materials emphasize interstitial lung diseases, idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, pulmonary hypertension, and bronchiectasis.
Does Qureight have public subscription pricing?
Qureight does not publish standard self-serve subscription prices in the available public materials. Its offering is presented as custom enterprise work.
Can Qureight analyze uploaded CT scans?
Yes. The platform supports CT scan intake through site uploads or SFTP transfers, followed by de-identification, curation, quality control, and analysis.
Is the Qureight Platform compliant for regulated trials?
Qureight states that the platform is GxP and 21 CFR Part 11 compliant. The company also lists ISO 13485:2016 and ISO 27001:2022 certifications.
Does Qureight offer synthetic control arms?
Yes. Its data science products combine quantitative imaging with real-world clinical data to support synthetic control arms and cohort analysis.
Community reviews
Be the first to share your experience.
Sign in to leave a review for Qureight.
Qureight Alternatives
Looking for alternatives to Qureight? Here are similar tools in the same category:
